Guido Ferrari

Guido Ferrari is a Professor in the Department of Surgery and Research Professor in Molecular Genetics and Microbiology at Duke University School of Medicine, with affiliate status at the Duke Global Health Institute. His work focuses on HIV immunology and vaccine development, particularly in South African contexts through the Infectious Diseases in Africa initiative.

His educational background includes an M.D. from the University of Genoa (1985), along with significant appointments at the University of Cape Town as Adjunct Visiting Professor (2012-2019) and Honorary Professor (2019-2024).

• M.D., University of Genoa (1985)
• Adjunct Visiting Professor, University of Cape Town (2012-2019)
• Honorary Professor, University of Cape Town (2019-2024)

Dr. Ferrari's research centers on HIV-1 immune responses, specializing in antibody-dependent cellular cytotoxicity (ADCC) and cytotoxic T cell mechanisms. His laboratory investigates how these responses eliminate HIV-infected cells and can be harnessed for vaccine design, with continuous NIH and Gates Foundation funding over 11 years. Current projects measure immune responses in resource-limited settings and mentor young investigators fighting AIDS, tuberculosis, and malaria.

His 2025 publications reveal dominant themes in HIV vaccine engineering, including neutralizing antibody development, B/T cell response dynamics in primates, and co-infection immunology with SARS-CoV-2. The work emphasizes computational vaccine design, Fc receptor functionality, and cross-protective immunity through international collaborations.

No specific scientific awards are mentioned in the provided text.

Dr. Ferrari actively mentors researchers in limited-resource countries through NIH/IAS initiatives. His laboratory secures substantial funding from:

• National Institutes of Health (Nonhuman Primate Core, EQAPOL, Multivalent mRNA HIV vaccine)
• Fred Hutchinson Cancer Center (HVTN Lab Center)
• Wistar Institute (DNA immunogen development)
• CRDF Global (India-Duke training exchange)

He directs the CFAR Immunology Core and ADCC laboratories for HVTN/CAVD/PAVEG at Duke, operating the Innate and Adaptive Cellular Cytotoxicity Laboratory. His team coordinates international ELISpot/ICS technology transfer workshops and investigates gene expression in NK/T cells during HIV infection, with expanded focus on vaccine-induced immune ontogeny.